Impaired kidney transplant survival in patients with antibodies to hepatitis C virus

Citation
Ma. Gentil et al., Impaired kidney transplant survival in patients with antibodies to hepatitis C virus, NEPH DIAL T, 14(10), 1999, pp. 2455-2460
Citations number
23
Categorie Soggetti
Urology & Nephrology
Journal title
NEPHROLOGY DIALYSIS TRANSPLANTATION
ISSN journal
09310509 → ACNP
Volume
14
Issue
10
Year of publication
1999
Pages
2455 - 2460
Database
ISI
SICI code
0931-0509(199910)14:10<2455:IKTSIP>2.0.ZU;2-#
Abstract
Background. With a few exceptions, most published studies do not show an in fluence of antibodies to the hepatitis C virus (HCV) on the success of a ki dney transplant. Methods. We studied all our renal transplant recipients who had received ki dneys from cadaver donors (n = 335) and had been treated with quadruple imm unosuppression (steroids, azathioprine, and antilymphocyte antibodies, foll owed by cyclosporin). We had information on the status of the hepatitis C a ntibodies before and/or after the transplant in 320 cases (95.5%, in 300, p re-transplant). Patients with HCV antibodies before and/or after the transp lant were considered to be HCV positive (HCV +). Results. The HCV + patients had more time in dialysis and a greater number of transfusions, hyperimmunized cases, and re-transplants. The evolution in the first post-transplant year was similar in both groups, but afterwards, the HCV + patients had proteinuria more often as well as worse kidney func tion. The survival rate of the graft was significantly less in the HCV + ca ses: 90.6, 68.3 and 51.0% at respectively 1, 5 and 10 years, compared with 91.5, 84.7 and 66.5% in HCV-patients (P < 0.01). The patient survival rate was: 96.4, 87.0, and 71.9% in the HCV + patients at 1, 5, and 10 years, com pared with 98.2, 96.0 and 90.0% in the HCV- cases respectively (P < 0.01). The differences remained the same in stratified studies according to time s pent in dialysis or pre/post-transplant evolution of HCV antibodies, even w hen immunologically highrisk patients were excluded. In multivariant analys is, the presence of HCV antibodies acted as a independent prognostic factor for the survival of the kidney and the patient: 3.0 (1.8-5.0) and 3.1 (1.2 -7.8) odds-ratio (95% of the confidence interval), respectively. The main c ause of death among HCV + patients was cardiovascular; there was no apparen t increase in mortality rate due to infections or chronic liver disease. Th e loss of organs was mainly due to chronic nephropathy or death with a func tioning kidney. Conclusion. The presence of hepatitis C antibodies, before or after transpl antation, is associated with a worse long-term survival rate for both the p atient and the transplanted kidney in our patients treated with quadruple t herapy.